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The objective of this study was to investigate the effect of pimobendane on 
echocardiographic parameters of right ventricular and atrial function in healthy cats. 
Eleven privately-owned, healthy adult cats were enrolled. Each cat underwent four 
echocardiographic examinations. The first and second examinations were performed 
one hour apart on Day 0. A third examination was done on day 1 followed by 
pimobendane (1.25 mg/cat) administration and a fourth examination one hour later. 
Parameters of right ventricular and atrial morphology and function were collected and 
compared among time points. 
No differences were found among echocardiographic variables in the three 
examinations before pimobendane was administered. The fourth examination 
showed that several parameters were affected by pimobendane administration. 
Specifically, right ventricular fractional shortening and peak velocity of systolic lateral 
tricuspid annular motion increased (P = 0.04, and P = 0.01, respectively), whereas 
right ventricular end-systolic internal diameter and right atrial minimal internal 
diameter decreased (P = 0.03, and P = 0.04, respectively). Right ventricular fractional 
area change, and tricuspid annular plane systolic excursion did not change. 
This novel study showed that pimobendane had positive effects on right ventricular 
and atrial function in healthy cats. Further studies are needed to determine whether 
pimobendane has similar effects in cats with cardiac diseases. 
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Das Ziel dieser Studie war, den Effekt von Pimobendan auf echokardiographische 
Funktionsparameter von rechtem Ventrikel und Vorhof zu untersuchen. 
Dazu wurden elf gesunde Katzen von privaten Besitzern in die Studie 
eingeschlossen. Jede Katze wurde am Tag 0 zweimal im Abstand von einer Stunde 
echokardiographisch untersucht. Am Folgetag wurde eine weitere Untersuchung 
durchgeführt, nach der jede Katze eine Dosis Pimobendan (1.25 mg/Katze) erhielt. 
Eine Stunde danach wurde eine weitere Echokardiographie durchgeführt. Die 
erhobenen Parameter der rechts ventrikulären und atrialen Funktion wurden 
zwischen den vier Zeitpunkten verglichen. 
Es fanden sich keine Unterschiede zwischen echokardiographischen Variablen vor 
der Pimobendan-Gabe. Es fanden sich mehrere Veränderungen nach Pimobendan-
Gabe. Die Herzfrequenz, die right ventricular fractional shortening und die peak 
velocity of systolic lateral tricuspid annular motion waren signifikant höher (P = 0.02, 
P = 0.04 und P = 0.01). Der rechtsventrikuläre end-diastolische Diameter und der 
rechts atriale minimale innere Diameter sanken signifikant (P = 0.03 und P = 0.04). 
Die rechtsventrikuläre fractional area change und die tricuspid annular plane systolic 
excursion wurden nicht verändert. 
Diese Studie zeigt einen positiven Effekt von Pimobendan auf die rechtventrikuläre 
und atriale Funktion bei gesunden Katzen auf. Weitere Studien sind gefragt, um zu 
zeigen, ob dieser Effekt auch bei Katzen mit Herzerkrankungen nachgewiesen 
werden kann. 
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Objectives - The objective of this study was to investigate the effect of pimobendan 
on echocardiographic parameters of right ventricular and atrial function in healthy 
cats.  
Materials and Methods - Eleven privately-owned, healthy adult cats were enrolled. 
Each cat underwent four echocardiographic examinations: the first and second 
examinations were performed one hour apart on Day 0, and the third and fourth 
examinations were done on Day 1. Right after the third echocardiographic 
examination, each cat received a single oral dose of pimobendan (1.25 mg/cat), and 
the fourth echocardiographic examination was carried out one hour later. Parameters 
of right ventricular and atrial morphology and function were collected and compared 
among time points.  
Results - No differences were found among echocardiographic variables in the three 
examinations before pimobendan was administered. The fourth examination showed 
that several parameters were affected by pimobendan administration. Specifically, 
heart rate, right ventricular fractional shortening and peak velocity of systolic lateral 
tricuspid annular motion increased (P = 0.02, P = 0.04, and P = 0.01, respectively), 
whereas right ventricular end-systolic internal diameter and right atrial minimal 
internal diameter decreased (P = 0.03, and P = 0.04, respectively). Right ventricular 
fractional area change and tricuspid annular plane systolic excursion did not change.  
Conclusion and relevance - This novel study showed that pimobendan had positive 
effects on right ventricular and atrial function in healthy cats. Further studies are 






Pimobendan is a phosphodiesterase III inhibitor and a calcium sensitizer. It is 
classified as an inodilator because of its two main effects, myocardial positive 
inotropy and arterial and venous vasodilation.1–5 In people and dogs, the positive 
inotropic effect of pimobendan is not associated with an increase in myocardial 
oxygen consumption,6-8 and in canine models of heart failure, this drug has been 
shown to have a positive lusitropic effect.6 Pimobendan has been well studied in 
dogs and is part of the standard treatment of dilated cardiomyopathy and 
myxomatous mitral valve disease.9–12 Interest in this cardiovascular drug as a 
possible treatment of subclinical and clinically overt cardiomyopathies in cats has 
recently emerged. Two retrospective studies reported that cats with non-taurine 
responsive dilated cardiomyopathy13 and hypertrophic cardiomyopathy (HCM)14 had 
prolonged survival times when pimobendan was part of their treatment protocol. The 
use of pimobendan also appeared to be beneficial as an adjunctive therapy for 
congestive heart failure in cats with heart disease of various etiologies.15 
To date, studies investigating the effects of pimobendan on echocardiographic 
variables in cats have focused on the left side of the heart.16–20 However, diseases 
such as arrhythmogenic cardiomyopathy, HCM or pulmonary hypertension, which 
involve the right ventricle (RV) or affect RV myocardial function and lead to right-
sided congestive heart failure, are well recognized in cats.21–25 It would therefore be 
important to determine whether an inodilator could improve RV systolic and diastolic 
function. To the authors’ knowledge, there is only one study that evaluated the effect 
of pimobendan on RV function in cats; it determined that pimobendan had no effect 




Therefore, the aim of the present study was to evaluate the effect of pimobendan on 
right-sided cardiac function in clinically healthy cats. We hypothesized that 
pimobendan has a positive effect on echocardiographic variables of RV and right 
atrial (RA) function. 
 
Materials and methods  
Animals 
The cats enrolled in this study had also been used for a previous study that focused 
on left atrial function.20 Owners of the cats signed an informed consent form, and the 
study was approved by the local ethical committee (protocol ID 873). 
Cats were enrolled in the study provided that they were one year of age or older, 
clinically healthy without evidence of cardiac disease or systemic illness, stress 
tolerant and not aggressive, had not received any medication in the previous year 
and had normal systolic blood pressure (<160 mmHg).26 Each cat underwent a 
complete physical examination, cardiac auscultation, systemic arterial blood pressure 
measurement using an oscillometric device (Vet25; SunTech), according to 
recommended guidelines,26 and an echocardiographic examination. Minimal blood 
work was carried out to exclude azotaemia and anaemia, and serum thyroxin levels 
were measured in cats over 6 years of age to exclude hyperthyroidism. The cats 








Four echocardiographic examinations were carried out in each cat. On day 0, a 
complete echocardiographic examination was done at time 0 (D0T0) and repeated 
one hour later (D0T1). On the following day, each cat underwent a third 
echocardiographic examination (D1T0). Cats were then given a single dose of 1.25 
mg pimobendan (Vetmedin 1.25 mg chewable tablet, Boehringer Ingelheim) 
administered orally, and a final echocardiographic examination was carried out one 
hour later (D1T1). The timing of the final echocardiographic examination was based 
on a pharmacokinetics study of pimobendan.27 The results of echocardiography were 
considered normal when subjective evaluation of all four cardiac chambers by the 
operator (MBT) revealed a normal volume and wall thickness, and when quantitative 
assessment yielded an end-diastolic LV wall thickness of <5.5 mm.28  
 
Echocardiography 
All echocardiographic examinations were done by a single board-certified cardiologist 
(MBT) using a single ultrasound system (iE33 ultrasound system; Philips Healthcare) 
with a phased-array probe (S12-4) and continuous ECG monitoring. Cats were 
unsedated and gently placed in right or left lateral recumbency to obtain the 
appropriate echocardiographic views.29 The morphological and functional 
echocardiographic variables of the right atrium and ventricle were obtained as 
follows. Right ventricular end-diastolic wall thickness, RV end-diastolic internal 
diameter (RVIDd) and RV end-systolic internal diameter (RVIDs) were measured 
using a leading-edge-to-leading-edge technique from M-Mode images obtained from 
a right parasternal short axis view at the level of the papillary muscles. Right 




using the formula: [(RVIDd – RVIDs) / RVIDd] x 100. Right ventricular end-diastolic 
(RVAd) and end-systolic (RVAs) areas were obtained from a left apical 4-chamber 
view optimized for the RV24 by tracing the internal border of the RV (Figure 1a). Right 
ventricular fractional area change (RV FAC) was calculated using the following 
formula and expressed as a percentage: [(RVAd – RVAs) / RVAd] x 100. Longitudinal 
systolic function was assessed by TAPSE recorded from a left apical 4-chamber view 
optimized for the RV from an M-mode image measuring the maximal metric 
difference of the lateral tricuspid annular plane with the cursor as parallel as possible 
to the RV free wall (Figure 1b). Peak velocity of systolic lateral tricuspid annular 
motion (TV S´) by pulsed wave Doppler was obtained from a left apical 4-chambers 
view optimized for the RV with a sample volume size of 2 mm (Figure 1c). Attention 
was paid to maintaining the position of the cursor as parallel as possible to the RV 
free wall. 
Right atrial maximum (RAmax) and minimum (RAmin) internal diameters were 
measured from an M-mode image obtained from the right parasternal long axis view 
optimized for the atria by using a leading-edge-to-leading-edge technique (Figure 
1d). Right atrial fractional shortening (RA FS) expressed as a percentage was 
calculated using the formula: [(RAmax - RAmin) / RAmax] x 100. Heart rate (HR) was 
calculated by measuring the aortic flow time interval from a left apical 5-chamber 
view using a pulsed-wave Doppler trace. 
All echocardiographic studies were stored off-line, and measurements were made by 
the same cardiologist (MBT) at the end of the study on anonymized and randomized 
images/loops to prevent information bias. A person not involved in the measurements 




software was used. For each parameter, a mean of three measurements was 
obtained on three consecutive cardiac cycles on the same frame/loop. 
 
Statistical analysis 
Data were tested for normality by visual examination of the plots and additionally 
using the Shapiro-Wilks test. Normal data are presented as mean ± standard 
deviation while non-normal data are presented as median and interquartile range. 
Normally distributed echocardiographic variables were compared between different 
time points using one-way repeated-measures ANOVA. Post-hoc pairwise 
comparisons among different times were done using Tukey’s multiple comparison 
test. Differences between non-normal variables were analysed using a repeated-
measures Friedman test followed by Dunn’s test. We evaluated within-day and 
between-day intra-observer variability with the echocardiographic values collected 
during the first three time points by calculating the respective coefficients of variation 
(CV). The percentage change for each variable after pimobendan administration was 
calculated and the number of cats whose percentage change exceeded the 
corresponding within-day CV was reported for each variable. Data analysis was done 
using a commercially available software program (Prism5, GraphPad Software Inc.). 




Eleven cats fulfilling the inclusion criteria were enrolled. Nine were domestic shorthair 




spayed females. The age was 5.6 ± 3.5 years, and the body weight was 4.8 ± 1.0 kg. 
Systolic arterial blood pressure was normal in all cats (138 ± 14 mmHg). The mean 
pimobendan dose administered was 0.27 ± 0.05 mg/kg. 
 
Echocardiographic variables 
No differences in echocardiographic variables were recorded among the first three 
examinations. Pimobendan administration led to significant changes in several 
variables (at D1T1) compared with baseline on the same day (D1T0). Specifically, 
HR, RV FS and TV S´ increased (P = 0.02, P = 0.04, and P = 0.01, respectively), 
while RVIDs and RAmin decreased (P = 0.03, and P = 0.04, respectively) (Figure 2). 
All echocardiographic results are presented in detail in Table 1. Within-day and 
between-day CVs are reported in Table 2. The mean percentage change for HR, 
RVIDs, RV FS, RAmin, RA FS and TV S´ after pimobendan administration exceeded 
the corresponding within-day CV. 
 
Discussion 
Our study provides novel information on the effect of pimobendan on RV and RA 
function in healthy cats. Oral administration of pimobendan was associated with an 
increase in RV function as evidenced by the results of several echocardiographic RV 
variables. The decrease in RAmin implied an increase in RA function as well.  
Not all variables of RV function were affected; TV S´ and RV FS increased after 
pimobendan administration, whereas RV FAC and TAPSE did not. Tricuspid annular 
plane systolic excursion and TV S´ are both measures of RV longitudinal function, 
which comprises the majority of global RV function in dogs and humans.30,31 The lack 




respect to changes in RV function compared with TV S´. This finding was in 
agreement with a study in human patients with advanced heart failure, in which 
levosimendan infusion produced an increase in TV S´ with no significant increase in 
TAPSE.32 Other studies in human medicine showed that RV S´ was better correlated 
with cardiac MRI-derived ejection fraction than with TAPSE.33,34  
In our study, RV FS increased after pimobendan administration indicating increased 
RV radial function. Right ventricular FS has been used in veterinary24 and human35 
medicine to assess RV systolic function. However, this variable is not well 
standardized for cats and in people it provides limited insight into global RV 
function.35 Furthermore, the intra-observer variability of this variable was poor in the 
present study.  
Interestingly, RV FAC, which represents both longitudinal and radial systolic RV 
function, did not change following pimobendan administration. Right ventricular FAC 
has been shown to be highly sensitive for RV dysfunction in humans.34 However, in 
our study, we found it not easy to obtain due to the small dimension of the heart and 
the difficulty in adequately visualize RV blood-tissue interface. Indeed, compared with 
the left ventricle, tracing the internal border of the RV is generally more difficult 
because of endocardial trabeculation, anatomical features and echocardiographic 
views.36,37 Intra-observer variability was poor for RVAs, which are used to calculate 
the RF FAC. In fact, RVAs had the highest CV making any parameter derived from 
these measurements of questionable diagnostic value. 
Heart rate increased after pimobendan administration compared with all prior time 
points. This may have been due to a positive chronotropic effect of pimobendan, 
which has been observed in ex-vivo studies on cardiomyocyte preparations from 




vasodilation (reduced afterload) may be another reason. An increase in HR can 
increase myocardial cell contractility (Bowditch effect) leading to increased systolic 
function.39 This effect may have positively influenced RV function in our study. A 
reduction in afterload attributable to pimobendan may also have contributed to 
changes in RV functional parameters, in addition to the direct inotropic effect of this 
drug on cardiomyocytes.36,40,41  
Improved RV function after a single dose of pimobendan was reported in 80 healthy 
dogs, based on increased TAPSE, RV FAC and RV S´ compared with pretreatment 
values.42 In human patients with pulmonary hypertension, TV S´ increased in the 
group receiving levosimendan infusion but not in the placebo group.32 When all 
results including ours are considered, they suggest that this inodilator has a positive 
effect on RV systolic function and TV S´ is a sensitive parameter for documenting the 
effect. 
Right atrial minimal internal diameter was reduced after pimobendan administration, 
but RA FS was not significantly increased, even though its mean percentage change 
after pimobendan administration was higher than the mean within-day CV. Lack of 
significance may be due to the small number of cats and the poor intra-observer 
variability of the measurement. Nevertheless, the reduction in RAmin also suggests a 
positive inotropic effect on RA cells. A direct effect has been shown in an ex-vivo 
study of human RA myocytes and in murine cells from the left atrium.44 
In addition, RA functional parameters are strongly dependent on loading conditions, 
which one would expect to be altered by pimobendan (namely, reduced preload and 
increased RV lusitropy).43 Similar to changes in the right ventricle, alterations in HR 
affecting RA preload and the associated Bowditch effect may have influenced our 




parasternal long axis view. This variable is also affected by translational motion of the 
heart base toward the apex during RV contraction, which therefore can affect 
measurements. 
The primary limitation of this study was the small sample size. It is possible that the 
study was underpowered to find significant differences for some echocardiographic 
RV functional parameters, especially those that may have had limited sensitivity. 
Another limitation was that only healthy cats were studied. The effect of a drug on 




Our results suggest that pimobendan has a positive effect on RV and RA function in 
healthy cats. Further studies are warranted to determine whether pimobendan can be 
used to treat right-sided cardiac disease in cats. 
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Legends to figures 
Fig. 1 Selected echocardiographic variables of right ventricular and atrial function in a 
healthy cat. (a) Right ventricular end-diastolic (left) and end-systolic (right) areas 
obtained from a left apical 4-chamber view optimized for the right ventricle measured 
by tracing the internal border of the right ventricle. (b) Tricuspid annular plane systolic 
excursion obtained from a left apical 4-chamber view optimized for the right ventricle 
from an M-mode image measuring the maximum metric difference of the lateral 
tricuspid annular plane (dotted lines) with the cursor as parallel as possible to the 
right ventricular free wall. (c) Peak velocity of systolic lateral tricuspid annular motion 
(dotted line) obtained from a left apical 4-chamber view optimized for the right 
ventricle using pulsed wave tissue Doppler imaging. (d) Right atrial maximum and 
minimum internal diameters measured on an M-mode image obtained from a right 
parasternal long axis view optimized for the atria using a leading-edge-to-leading-
edge technique 
 
Figure 2 Echocardiographic variables that changed from D1T0 to D1T1 (one hour 
after pimobendan administration) in a group of 11 healthy cats. HR = heart rate, RA 
min = right atrial minimum internal diameter, RVIDs = right ventricular internal 
diameter in systole, RV FS = right ventricular fractional shortening, TV TDI S´ = Peak 
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Table 1. Echocardiographic variables obtained in 11 healthy cats at two different time points without (DAY 0) and with 
(DAY 1) administering one single dose of pimobendan 
DAY 0 DAY 1 
Variable Time 0 Time 1h Time 0 
Time 1h 
(Pimobendan) 
overall P value 
Heart rate (bpm) 176.5 ± 28.3 173.3 ± 30.1 175.2 ± 34.7 199.8 ± 37.8*,##,§ <0.001 
RVIDd (mm) 5.2 ± 1.2 5.0 ± 1.2 4.9 ± 1.3 4.3 ± 1.0 0.115 
RVIDs (mm) 2.6 (2.1-2.9) 2.6 (2.1-3.5) 2.9 (1.5-3.8) 1.9 (1.1-2.2)#,§ 0.018 
RV FS (%) 47.0 ± 10.5 46.1 ± 12.0 43.1 ± 13.0 57.6 ± 12.8#,§ 0.018 
RVFWd (mm) 2.5 ± 0.5 2.5 ± 0.3 2.4 ± 0.3 2.5 ± 0.2 0.910 
RVAd (cm2) 1.2 (1.1-1.6) 1.5 (1.4-1.8) 1.4 (1.2-1.7) 1.4 (1.2-1.7) 0.132 
RVAs (cm2) 0.5 ± 0.2 0.6 ± 0.2 0.5 ± 0.2 0.5 ± 0.2 0.085 
RV FAC (%) 54.5 (52.9-72.7) 63.2 (50.0-69.2) 66.7 (55.0-73.3) 68.8 (53.9-71.4) 0.058 
RAmax (mm) 11.4 ± 1.1 10.9 ± 1.3 10.8 ± 1.2 10.1 ± 1.1* 0.042 
RAmin (mm) 8.6 ± 1.5 7.9 ± 1.4 7.9 ± 1.5 6.8 ± 1.3**,§ 0.007 
RA FS (%) 25.0 ± 9.5 27.6 ± 8.1 27.0 ± 9.0 32.4 ± 9.9 0.102 
TAPSE (mm) 8.4 ± 1.2 9.5 ± 1.3 9.1 ± 1.7 9.1 ± 1.7 0.248 
TV S' 11.4 (8.9-12.3) 10.4 (8.6-11.3) 10.4 (9.6-11.9) 13 (11.4-15.6)#,§ 0.006 
Data are expressed as mean ± standard deviation or median (interquartile range). 
* = P < 0.05 compared to DAY 0 Time 0
**  = P < 0.01 compared to DAY 0 Time 0 
#  = P < 0.05 compared to DAY 0 Time 1h 
## = P < 0.01 compared to DAY 0 Time 1h 
§ = P < 0.05 compared to DAY 1 Time 0
RAmax and RAmin = right atrial maximal and minimal internal diameter, respectively; RA FS = right atrial fractional shortening;
RVAd and RVAs = right ventricular area in diastole and systole, respectively; RV FAC = right ventricular fractional area change;
RV FS = right ventricular fractional shortening; RVFWd = right ventricular free wall thickness in diastole; RVIDd and RVIDs =
right ventricular internal diameter in diastole and systole, respectively; TAPSE = tricuspid annular plane systolic excursion; TV




Table 2. Within-day and between-day CV of right ventricular and atrial echocardiographic variables in 11 healthy cats and their 
percentage change after a single dose of pimobendan. 
Variable Within-day CV (%) Between-day CV (%) 
% change after Pimobendan 
(range)* 
Number of cats** 
Heart rate (bpm) 6.6 9 15.3 (-5.3 to 44) 11 
RVIDd (mm) 17.1 19.8 -10.9 (-35.8 to 16.1) 4 
RVIDs (mm) 18.9 22.7 -29.9 (-68.4 to 35.7) 8 
RV FS (%) 14.7 22.8 47.3 (-15-5 to 198.8) 8 
RVFWd (mm) 7.5 9.3 4.2 (-14.3 to 21.7) 9 
RVAd (cm2) 19.3 11.9 2.7 (-35 to 33.3) 6 
RVAs (cm2) 21.9 27.3 -3.5 (-50 to 25) 5 
RV FAC (%) 13.7 11.7 0.3 (-23.1 to 12.5) 1 
RAmax (mm) 8.5 8.8 -6.2 (-23.5 to 7.5) 4 
RAmin (mm) 8.1 9.4 -12.7 (-33 to 14.8) 8 
RA FS (%) 18.8 25.6 30.3 (-43.3 to 107.9) 10 
TAPSE (mm) 10.4 11.7 1.8 (-23.5 to 29.7) 8 
TV S' 9.4 17.4 33.2 (-6.8 to 72.1) 8 
*percentage change of the value for each variable after pimobendan administration. **number of cats in which the percentage
change after pimobendan administration exceeded the within-day CV. Percentage changes that exceed the within-day CV are
shown in bold.
CV = coefficient of variation; RVIDd and RVIDs = right ventricular internal diameter in diastole and systole, respectively; RV FS 
= right ventricular fractional shortening; RVFWd = right ventricular free wall thickness in diastole; RVAd and RVAs = right 
ventricular area in diastole and systole, respectively; RV FAC = right ventricular fractional area change; RAmax and RAmin = right 
atrial maximum and minimum diameter, respectively; RA FS = right atrial fractional shortening; TAPSE = tricuspid annular plane 
systolic excursion; TV S´ = peak velocity of systolic lateral tricuspid annular motion 
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